US 12,472,295 B2
Dialysis system having adaptive prescription management
Alex Anping Yu, Safety Harbor, FL (US); James Grayson, Toronto, CA (US); and Robert W. Childers, New Port Richey, FL (US)
Assigned to Baxter International Inc., Deerfield, IL (US); and Baxter Healthcare SA, Glattpark (CH)
Filed by BAXTER INTERNATIONAL INC., Deerfield, IL (US); and BAXTER HEALTHCARE SA, Glattpark (CH)
Filed on Mar. 4, 2024, as Appl. No. 18/594,854.
Application 16/141,353 is a division of application No. 14/518,274, filed on Oct. 20, 2014, granted, now 10,307,524, issued on Jun. 4, 2019.
Application 18/594,854 is a continuation of application No. 17/727,334, filed on Apr. 22, 2022, granted, now 11,918,721.
Application 17/727,334 is a continuation of application No. 16/871,558, filed on May 11, 2020, granted, now 11,311,658, issued on Apr. 26, 2022.
Application 16/871,558 is a continuation of application No. 16/141,353, filed on Sep. 25, 2018, granted, now 10,646,634, issued on May 12, 2020.
Application 14/518,274 is a continuation of application No. 13/679,525, filed on Nov. 16, 2012, granted, now 8,871,095, issued on Oct. 28, 2014.
Application 13/679,525 is a continuation of application No. 13/274,012, filed on Oct. 14, 2011, granted, now 8,313,642, issued on Nov. 20, 2012.
Application 13/274,012 is a continuation of application No. 12/170,220, filed on Jul. 9, 2008, granted, now 8,057,679, issued on Nov. 15, 2011.
Prior Publication US 2024/0207498 A1, Jun. 27, 2024
Int. Cl. A61M 1/16 (2006.01); A61M 1/14 (2006.01); A61M 1/28 (2006.01); A61M 1/34 (2006.01); B01D 61/30 (2006.01); B01D 61/32 (2006.01); G16H 20/40 (2018.01)
CPC A61M 1/282 (2014.02) [A61M 1/155 (2022.05); A61M 1/159 (2022.05); A61M 1/16 (2013.01); A61M 1/1603 (2014.02); A61M 1/28 (2013.01); A61M 1/281 (2014.02); A61M 1/287 (2013.01); A61M 1/341 (2014.02); B01D 61/30 (2013.01); B01D 61/32 (2013.01); G16H 20/40 (2018.01); A61M 1/1522 (2022.05); A61M 2205/18 (2013.01); A61M 2205/3303 (2013.01); A61M 2205/3327 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3576 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/502 (2013.01); A61M 2230/005 (2013.01); A61M 2230/30 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A peritoneal dialysis system comprising:
at least one pump;
a memory device configured to store:
therapy prescriptions including:
a high ultrafiltration (“UF”) therapy prescription for removing a first amount of ultrafiltrate from a patient, and
a standard UF therapy prescription for removing a second amount of ultrafiltrate from the patient, the second amount of ultrafiltrate being less than the first amount of ultrafiltrate, or a low UF therapy prescription for removing a third amount of ultrafiltrate from the patient, the third amount of ultrafiltrate being less than the second amount of ultrafiltrate, and
an expected UF removal trend or an expected UF removal minimum value; and
a logic implementer communicatively coupled to the memory device and configured to:
receive UF removed data related to performing the high UF therapy prescription or the low UF therapy prescription or the standard UF therapy prescription for a peritoneal dialysis treatment,
use the UF removed data to form or update a moving average UF removed trend,
compare the moving average UF removed trend to the expected UF removal trend or the expected UF removal minimum value,
when the moving average UF removed trend is below the expected UF removal trend or the expected UF removal minimum value, provide a recommendation, via a user interface, that the high UF therapy prescription should be selected for a next peritoneal dialysis treatment,
receive a selection of the high UF therapy prescription for the next peritoneal dialysis treatment, and
control the at least one pump based on the high UF therapy prescription to perform the next peritoneal dialysis treatment.